Diabetes News and Innovations

Orange Biomed’s at-home A1C testing device could be a potential disrupter in prediabetes and diabetes care. The Orange Biomed device, called OBM Rapid A1C, also does not use protein reagents, eliminating the need for frequent calibrations, Ko said. And the new technology is not affected by variance in hemoglobin proteins…
Denver7 News feature on Orange Biomed's efforts to improve A1C readings for Black individuals with diabetes. The article highlights the company's portable device for more accurate readings, addressing red blood cell lifespan differences. The device is in clinical trials and pending FDA clearance.
Orange Biomed is making a portable device to produce more accurate A1C readings for Black diabetics. Current tests show higher numbers due to red blood cell lifespan differences. This device helps to improve diabetes care for better results. It is in clinical trials and pending FDA clearance.
Diabetes is a typical chronic disease that affects more than 500 million patients worldwide. In the early stages, there are no clear symptoms, but if left untreated, complications and treatment burdens increase exponentially. Therefore, diabetes management goes beyond simply measuring blood sugar levels every day…
The future of healthcare is on display at CES 2025, with five innovative digital health startups backed by Digital Healthcare Partners (DHP) showcasing groundbreaking technologies poised to revolutionize wellness and patient care.
Orange Biomed is developing a small medical device called ‘OBM rapid A1c’ that can measure glycated hemoglobin levels, which are essential for diabetes management, at home with a single blood sample based on microfluidic technology. In particular, Orange Biomed plans to target the U.S. market, where medical accessibility is low…
Five portfolio startups invested by Digital Healthcare Partners (DHP) will participate in the world’s largest information technology (IT) and home appliance exhibition, ‘CES 2025’… They plan to network with local experts and industry insiders at CES and explore opportunities to enter global markets.
“Enhancing Healthcare Equity with Cutting-Edge Medical Devices” Orange Biomed will showcase its portable HbA1c monitor, OBM rapid A1c… The OBM rapid A1c is a groundbreaking device designed to simplify diabetes management by enabling accurate and convenient hemoglobin A1c testing at home.
Orange Biomed announced that it will be participating in Eureka Park at CES 2025, held in Las Vegas, Nevada, USA from January 7 to 10, and will be introducing the portable glycated hemoglobin measuring device, ‘OBM rapid A1c’.
“We will increase medical equity with cutting-edge medical devices!” Orange Biomed announced that it will participate in the ‘K-Startup Pavilion’ at CES 2025…
Bio startup Orange Biomed is entering the global market with its personal glycated hemoglobin (HbA1c) measuring medical device. Based on its miniaturization technology…
US Daily Ledger
Demo the Revolutionary Microfluidic Home-based A1C Testing Kit, a Breakthrough Technology Application Recognized by Industry Leaders…
이데일리
At COMEUP, Orange Biomed, which possesses technology to monitor diabetes with a single drop of blood, is a Rocket League company that received Series A investment…
레기뉴스
Diabetes is a silent disease. For management, glycated hemoglobin must be measured. With Orange Biomed, the periodic management of glycated hemoglobin is possible…
Orange Biomed successfully concludes Series A1 investment
Recognition of clinical research results for innovative microfluidic technology-based portable glycated hemoglobin meter, participation in CES Eureka Park in 2025 to fully advance into the US market.
The Good Men Project | Featured Content Of Yeaseul Park about the Orange Biomed’s New Diabetes Device
Yeaseul Park, CEO of Orange Biomed, is a Forbes 30 Under 30 honoree. What is the efficacy of this new device? Interview by Scott Douglas Jacobsen. Park discusses the development of their innovative A1C diabetes management device…
Orange Biomed Contribute to BIOSPECTRUM Asia edition, volume 19
“Ultimately, this leads to better health outcomes by making diabetes management more accessible and proactive,” said Yeaseul Park, Co-Founder and Co-President  Orange Biomed, USA. 
'ORANGE BIOMED TO SHOWCASE FIRST-EVER MICROFLUIDIC-BASED A1C TEST AT MEDICA 2024 DURING DIABETES AWARENESS MONTH' - a news covered by smb world report
Award-Winning, Novel Single-Cell Analysis Technology in a Device Designed to Accurately Measure A1C from One…
'ORANGE BIOMED RECOGNIZED GLOBALLY WITH KHF INNOVATION AWARD FOR PIONEERING MICROFLUIDIC TECHNOLOGY APPLICATION' - a news covered by new product watchh
OBM rapid A1c is a Breakthrough Microfluidic-Based Testing Device to Redefine Diabetes Management Worldwide…
'Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting.' News Covered By drug delivery business
Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting…
'ORANGE BIOMED UNVEILS WORLD’S FIRST MICROFLUIDIC-BASED A1C TEST AT THE DIABETES TECHNOLOGY MEETING’S STARTUP SHOWCASE' - News Covered By EinPresswire
Attendees get an early preview of Orange Biomed’s revolutionary A1C testing method, recognized as a groundbreaking solution with anticipated release in 2025…
Download the Orange Biomed Media Kit
For patients with diabetes and healthcare professionals that want an easy-to-use portable A1c testing device, Orange Biomed…
Orange Biomed revealed its latest technology at the 83rd Scientific Sessions of the American Diabetes Association (ADA)
In the United States, more than 1 in 5 people with diabetes do not know they have diabetes, and they are at higher risk…
'The Role of Corporate Social Responsibility for U.S. Market Entry and Expansion – Expediting Value Across Industries Through Community Efforts' - Orange Biomed Featured In Fortune Korea News
When S. Korean companies attempt to enter or expand within the U.S. market, they often confront obstacles due to their…
Orange Biomed news covered By MTO
Glycated hemoglobin, a glycated protein in which sugar is bound to hemoglobin in red blood cells, is the most important…
Biotimes took an interview of Orange Biomed's CEO.
Glycated hemoglobin, a glycated protein in which sugar is bound to hemoglobin in red blood cells, is the most important…
'Orange Biomed selected as 2023 “First Penguin ” by Korea Credit Guarantee Fund', News Covered By Asia Economy
Orange Biomed, a venture company developing a microfluidic-based glycated hemoglobin measurement medical device…
Orange Biomed Featured On diabetes journals
In the United States, more than 1 in 5 people with diabetes do not know they have diabetes, and they are at higher risk…
Orange Biomed News covered by MPO-MAG
Orange Biomed, a diabetes management tech startup, has launched its OBM rapid A1c test in the U.S. OBM rapid A1c…
Orange Biomed Featured on hospimedica
Diabetes stands as a primary contributor to mortality rates and accounts for a significant portion of healthcare expenses…
Orange Biomed News Covered By medical device Network
Healthcare start-up Orange Biomed has launched its pocket-sized, reusable OBM rapid A1c test in the US to fill the testing…
Orange Biomed Featured On 360dx
South Korean startup Orange Biomed announced Wednesday its US launch with…
Orange Biomed News covered by Sandiegometro
Orange Biomed, a North Carolina health care startup with cutting-edge diabetes management technology…
Orange Biomed News is covered By Mass Device
Orange Biomed announced today that it commenced a U.S. launch as it looks to fill testing gaps for pre-diabetes and diabetes…
Orange Biomed Featured On Medical device news magazine
Orange Biomed, a North Carolina health care startup with cutting-edge diabetes management technology…
Orange Biomed is featured in the article '11 diabetes tech startups you need to know', by medical design and Outsourcing
The diabetes technology space is one that’s always innovating. From continuous glucose monitoring to insulin pumps…
OBM Rapid A1c is featured in the article '11 Diabetes Tech Startups You Need to Know,' by Drug Delivery Business.
The diabetes technology space is one that’s always innovating. From continuous glucose monitoring to insulin pumps and…
'Orange Biomed Highlighted as Top Technology Presented in Pitchfest Sponsored by Mayo Clinic Collaborative Services', the news Covered by pharm news
The number of patients with diabetes and pre-diabetes is rapidly increasing not only in Korea but also around the world…
'Orange Biomed Highlighted as Top Technology Presented in Pitchfest Sponsored by Mayo Clinic Collaborative Services' - News Covered By pharm News | DAC
Last February, BDMT Global, an American global business development company, successfully completed the ‘DAC…
Orange Biomed Co-Founder, Yeaseul Park, Featured in Forbes Korea’s 30 Under 30 List
Orange Biomed, established in 2021, succeeded in developing the world’s first glycated hemoglobin measuring…
Orange Biomed Interview By MIT Technology
Orange Biomed developed a glycated hemoglobin analyzer using microfluidic technology the size of red blood cells…
Orange Biomed Highlighted in Fortune Korea Expert Opinion Report
In 2021, CEOWorld Magazine ranked S. Korea to be #1 among global healthcare systems, hardly its first Health Care Index…
Orange Biomed Featured In CB Insights
For over 100 years, insulin has revolutionized diabetes care by providing patients with a treatment to help manage the disease…
Orange Biomed News is covered by etnews
A technology that can check glycated hemoglobin, which previously had to be measured using expensive…
Medical Device Startup 'Orange Biomed' Attracts 1.6 Billion Won in Pre-A Investment| Orange Biomed Featured On platum
‘Orange Biomed’, a diabetes in vitro diagnostic medical device startup, attracted 1.6 billion won in pre-Series A round investment…
Microengineered Materials with Self-Healing Features for Soft Robotics” Article Recognized as Top Downloaded Article by Wiley
Soft bodied invertebrates and vertebrates have been an inspiration for the development of soft robots.[1, 2] Compared to robots…